Description of Chewtadzy
Chewtadzy (tadalafil) acts as a selective inhibitor of phosphodiesterase type 5 (PDE5), an enzyme that affects blood flow in the penis. Its empirical formula is C22H19N3O4, boasting a molecular weight of 389.41.
CHEWTADZY (tadalafil) Structural Formula Illustration
These chewable tablets are available in various strengths—5 mg, 10 mg, or 20 mg of tadalafil—and are characterized by their blue color and uncoated design, ensuring a palatable administration experience by incorporating flavors like bubblegum along with inactive ingredients such as lactose monohydrate and magnesium stearate.
Uses for Chewtadzy
Erectile Dysfunction
Chewtadzy is primarily prescribed for treating erectile dysfunction (ED), which refers to the inability to achieve or maintain a sufficient erection for sexual activity.
Benign Prostatic Hyperplasia
Additionally, it is indicated for alleviating symptoms linked to benign prostatic hyperplasia (BPH), such as difficulty in urination and increased frequency of urination.
Erectile Dysfunction and Benign Prostatic Hyperplasia
Chewtadzy effectively addresses patients suffering from both ED and BPH, permitting a multifaceted approach to managing these conditions simultaneously.
Limitations of Use
- Use alongside finasteride for BPH initiation is recommended for up to 26 weeks, as incremental benefits may diminish thereafter.
- This medication should not be utilized for once-daily ED treatment due to dosage limitations.
Dosage for Chewtadzy
Important Dosage and Administration Instructions
- Patients should chew Chewtadzy tablets thoroughly before swallowing; whole swallowing is not recommended.
- Chewtadzy can be taken with or without food, depending on individual preference.
- Avoid splitting or breaking tablets to ensure accurate dosing is maintained.
Recommended Dosage for Use as Needed for Erectile Dysfunction
- The advised initial dose for erectile dysfunction (ED) is 10 mg, taken prior to sexual activity, not exceeding once daily.
- Given individual tolerability and effectiveness, the dosage may be escalated to 20 mg or reduced to 5 mg as needed.
Recommended Dosage for Once Daily Use for Benign Prostatic Hyperplasia
In the context of benign prostatic hyperplasia (BPH), the suggested dosing is 5 mg taken once daily, without regard to timing of sexual activity.
Recommended Dosage in Patients with Renal Impairment
For patients experiencing renal impairment, dosage adjustments may be required based on creatinine clearance; healthcare providers will determine specific recommendations.
Recommended Dosage in Patients with Hepatic Impairment
For those with mild or moderate hepatic impairment, Chewtadzy may be prescribed with caution, while it is contraindicated in patients with severe hepatic impairment.
Side Effects for Chewtadzy
Adverse reactions frequently reported include:
- Headache: One of the most common side effects.
- Dyspepsia: This indicates discomfort in the upper abdomen.
- Back pain: It may arise within hours of taking the drug.
- Nasopharyngitis: Common cold-like symptoms may appear.
- Myalgia: Muscle pain may affect various parts of the body.
- Pain in extremities: Discomfort can occur in arms and legs.
Serious Adverse Effects
Mores serious reactions that require immediate attention include:
- Cardiovascular incidents, including stroke or heart attack.
- Vision loss or other ophthalmic issues requiring intervention.
- Hearing loss or tinnitus, often accompanied by dizziness.
Reporting Side Effects
Any adverse effects experienced should be promptly reported to your healthcare provider. Additionally, the FDA can be contacted at 1-800-FDA-1088 for side effect reporting.
Drug Interactions for Chewtadzy
Potential for Pharmacodynamic Interactions
Nitrates
It is imperative that Chewtadzy not be taken in conjunction with any form of organic nitrates, as this can result in severe hypotension.
Alpha-Blockers
Care should be exercised when combining Chewtadzy with alpha-blockers, since both medications lower blood pressure, which may lead to compounded hypotensive effects.
Alcohol
High levels of alcohol consumption can amplify the hypotensive effects of Chewtadzy, potentially resulting in dizziness or fainting spells.
Warnings for Chewtadzy
Caution should be taken to thoroughly evaluate the cardiovascular condition of patients prior to prescribing Chewtadzy, as sexual activity can increase cardiovascular risk.
Sudden Vision Loss
Healthcare providers should monitor patients for sudden vision loss post-administration of Chewtadzy, as this could indicate serious underlying medical conditions.
Priapism Risk
Patients should be educated about the risk of prolonged erections and the importance of seeking immediate medical attention if an erection persists beyond 4 hours.
Patient Information for Chewtadzy
Patients should receive counseling on the correct administration of Chewtadzy. It should be thoroughly chewed before swallowing and can be taken with or without food.
It is essential to understand that Chewtadzy does not provide protection against sexually transmitted diseases, including HIV or AIDS, and responsible use alongside protective measures is advised.